web analytics

The Inside Scoop on Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX)

0

Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX) has been seeing a lot of action in recent months. Reverse merger plays have been some of the biggest movers in small caps in recent years and CTYX has been no exception running out of sub penny land to highs near $0.03.

As CTYX has been spiking up the charts it has been attracting legions of shareholders including many old time speculators and transforming into a volume leader in small caps.

Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX) is a clean shell incorporated in Florida in 2007. The Company has seen a number of reincarnations as Growth Industries, Inc, Fragrance Express, Inc. National Boston Medical, Inc. and Storage Innovation Technologies, Inc before changing its name to Connectyx Technologies Holdings Group in October 2007.

The incoming Company on this RM is SunMed Advisors, LLC; a leading advisor to Life Science companies ranging from those still in clinical stage to those with commercial products on the market. The Company brings value to all stages of transactions, from initiation and sourcing, through closing. Our primary focus is on cross boarder licensing. Our management team has over 30 years of experience successfully completing transactions.

The principals behind SunMed are Paul M. Michaels who has been appointed Interim CEO and Director as well as Dr. Barry A. Ginsberg and Brandon Michaels who join the BOD.

Jon Pevzner, former President and Director, has resigned and Paul M. Michaels was appointed Interim CEO and Director. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences.

To Find out the inside Scoop on CTYX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CTYX

According to new management CTYX is currently in the process of updating financials to become compliant with OTCMarkets and has appointed Jonathan D. Leinwand, PA as Legal Counsel. CTYX will continue to update shareholders on a new business plan through news releases, website updates and OTCMarkets filings as the company moves forward.

New CEO Paul M Michaels is a harvard business graduate and founder of Sunmed Advisors and NobelPharma. For the past two decades, Mr. Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few.

Paul began his career as Co-Founder, Executive Vice President and Board Member of Global Capital Group, a publicly traded corporate finance firm on Wall Street where he structured, financed and advised transactions in multiple spaces utilizing a variety of financial vehicles including private placements and Initial Public Offerings.

https://twitter.com/Yenom99/status/1243625659106287617

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $3 million market valuation CTYX is the sub penny to trade huge volume and land among the top 10 most active stocks in small cap. Reverse merger plays have been some of the biggest movers in small caps in recent years and CTYX has been no exception running out of sub penny land to highs near $0.03. As CTYX has been spiking up the charts it has been attracting legions of shareholders including many old time speculators and transforming into a volume leader in small caps. The incoming Company on this RM is SunMed Advisors, LLC; a leading advisor to Life Science companies ranging from those still in clinical stage to those with commercial products on the market.  We will be updating on CTYX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CTYX.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CTYX either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.